Lung Cancer Study Reveals Autophagy-Related Risk Model for Predicting Recurrence and Immunotherapy Response

Strategic Insights -

Research conducted by a team of scientists from Central South University has shed light on the role of autophagy in lung adenocarcinoma (LUAD), a type of non-small cell lung cancer. The study, published in PeerJ, found that an autophagy-related risk model can effectively predict recurrence and immunotherapy response in stage I LUAD patients.

According to the study, autophagy is a double-edged sword in tumor development and anti-tumor therapy resistance. However, the prediction of relapse and therapeutic response in LUAD patients with stage I based on the signature of autophagy remains unclear. The researchers established an autophagy score based on 19 autophagy genes and found that MAP1LC3B played a crucial role in the protein-protein interaction network and was down-regulated in tumor tissues. The study also discovered that the autophagy score was an independent predictor for relapse and suppressed the tumor immune microenvironment.

Key Takeaways:

  • A comprehensive analysis identified an autophagy-related risk model for predicting recurrence and immunotherapy response in stage I lung adenocarcinoma.
  • The study found that autophagy is a double-edged sword in tumor development and anti-tumor therapy resistance.
  • The autophagy score was established based on 19 autophagy genes, with MAP1LC3B playing a crucial role in the protein-protein interaction network.
  • The autophagy score was an independent predictor for relapse and suppressed the tumor immune microenvironment.
  • The study used gene expression data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database to identify autophagy-associated genes.
  • Protein-protein interaction (PPI) analysis revealed crucial genes involved in the autophagy pathway.
  • Gene Set Enrichment Analysis (GSEA) was used to reveal the molecular features of patients with stage I LUAD.
  • The ESTIMATE algorithm was applied to estimate the tumor immune infiltration, and the TIDE score was used to assess therapeutic response.
  • The study identified 19 autophagy genes, including MAP1LC3B, which was down-regulated in tumor tissues.

Statistics:

  • 19 autophagy genes were identified in the study, with MAP1LC3B playing a crucial role.
  • The autophagy score had a high predictive value for recurrence and immunotherapy response in stage I LUAD patients (AUC = 0.701, 0.836, and 0.818, respectively at 1, 2, and 3 years).
  • Multivariate regression analysis indicated that the autophagy score was an independent predictor for relapse (P < 0.001).

Sources:

  • PeerJ. A comprehensive analysis identified an autophagy-related risk model for predicting recurrence and immunotherapy response in stage I lung adenocarcinoma. 2025, 13():e19366.
  • Central South University. Department of Pathology, Second Xiangya Hospital, Changsha, People's Republic of China.